EU pharmacovigilance law introduces 'more pain than gain', say companies
This article was originally published in SRA
The two main objectives of the EU pharmacovigilance legislation were to strengthen and rationalize existing drug surveillance systems. After almost a year of the law coming into effect, many drug companies believe that the tenet of rationalization has been somewhat lost along the way.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.